Principal Financial Group Inc Atea Pharmaceuticals, Inc. Transaction History

Principal Financial Group Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 29, 2024	SELL	$3.31 - $4.04 $46,171 - $56,353	-13,949 Reduced 54.97%	11,425 $37,000
Q1 2024 Apr 29, 2024	SELL	$3.09 - $4.56 $6,451 - $9,521	-2,088 Reduced 7.6%	25,374 $102,000
Q4 2023 Feb 07, 2024	SELL	$2.8 - $3.35 $8,204 - $9,815	-2,930 Reduced 9.64%	27,462 $83,000
Q3 2023 Nov 02, 2023	BUY	$3.0 - $3.79 $13,722 - $17,335	4,574 Added 17.72%	30,392 $91,000
Q2 2023 Aug 07, 2023	BUY	$3.21 - $5.06 $11,639 - $18,347	3,626 Added 16.34%	25,818 $96,000
Q1 2023 May 09, 2023	BUY	$3.0 - $4.97 $7,932 - $13,140	2,644 Added 13.53%	22,192 $74,000
Q4 2022 Feb 09, 2023	BUY	$4.35 - $6.17 $8,878 - $12,592	2,041 Added 11.66%	19,548 $94,000
Q3 2022 Nov 09, 2022	BUY	$5.49 - $8.79 $22,953 - $36,750	4,181 Added 31.37%	17,507 $100,000
Q2 2022 Aug 10, 2022	BUY	$5.33 - $8.18 $71,027 - $109,006	13,326 New	13,326 $94,000
Q4 2021 Feb 09, 2022	SELL	$7.67 - $44.59 $46,633 - $271,107	-6,080 Closed	0 $0
Q3 2021 Nov 09, 2021	BUY	$21.33 - $35.06 $129,686 - $213,164	6,080 New	6,080 $213,000

112

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $271M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.